PDF(1269 KB)
Cost‑utility analysis of encorafenib plus cetuximab combined with mFOLFOX6 as first‑line therapy for BRAF V600E‑mutant metastatic colorectal cancer
ZHU Tongming, YI Jia, LI Wenqiang, ZHU Xiaowei, SHEN Aizong
Chinese Journal of Hospital Pharmacy ›› 2026, Vol. 46 ›› Issue (6) : 683-690.
PDF(1269 KB)
PDF(1269 KB)
Cost‑utility analysis of encorafenib plus cetuximab combined with mFOLFOX6 as first‑line therapy for BRAF V600E‑mutant metastatic colorectal cancer
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
